Based on the finding that PCK2 inhibits tumor progression by activating endoplasmic reticulum stress in RCC cells, we used immunohistochemistry (IHC) and western blot to assess the level of endoplasmic reticulum stress in vivo and to evaluate the malignancy of the subcutaneous tumors formed. This evidence concerns the gene PCK2 and renal cell carcinoma.